

[Dexamethasone](#)

Statut de médicament essentiel

Section:

[3. Antiallergics and medicines used in anaphylaxis](#)

Codes ATC: [H02AB02](#)

EMLc

Indication

Allergic or hypersensitivity conditions of unspecified type Code ICD11: [4A8Z](#)

INN

Dexamethasone

Type de médicament

Chemical agent

Type de liste

Liste de base

Formulations

Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate) (EMLc) ; 2 mg per 5 mL (as sodium phosphate)

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)

Oral > Solid > tablet: 0.5 mg (as dexamethasone base) ; 0.75 mg (as dexamethasone base) ; 1.5 mg (as dexamethasone base) ; 2 mg (as dexamethasone base) ; 4 mg (as dexamethasone base)

Historique des statuts LME

Ajouté pour la première fois en 1984 ([TRS 722](#))

Modifié en 2007 ([TRS 950](#))

Modifié en 2025 ([TRS 1064](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets](#).

Wikipédia

[Dexamethasone](#)

DrugBank

[Dexamethasone](#)

Résumé des preuves et recommandation du comité d'experts



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of dexamethasone oral liquid 0.5 mg/5 mL (as sodium phosphate) to the EMLc; - the addition of dexamethasone tablets 0.5 mg, 0.75 mg, 1.5 mg and 4 mg (as dexamethasone base) to the EML and EMLc; - to modify the listings to reflect the amount of dexamethasone in terms of dexamethasone salt or dexamethasone base.